By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today announced its first-quarter revenues rose 67 percent year over year to C$2.5 million ($2.6 million).

The C$2.5 million figure compares to C$1.5 million in revenues from a year ago. Clinical product revenues increased to C$1.8 million from C$1.2 million, while non-clinical product revenues climbed to C$266,285 from C$188,125 a year ago. Contract service revenues rose to C$448,104 from C$146,945 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.